FBR affirms BioDelivery Sciences International, Inc. (NASDAQ: BDSI) with an Outperform rating and $17 price target after the company and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

FDA Approval of BELBUCA™ (CIII) (Buprenorphine HCl) Buccal Film for Chronic Pain Triggers Milestone Payment of $50 Million to BioDelivery Sciences from Partner Endo PharmaceuticalsOctober 26, 2015 7:00 AM Endo Int'l (ENDP), BioDelivery Sciences (BDSI) Announce FDA Approval of BELBUCA as Chronic Pain TreatmentOctober 26, 2015 6:26 AM U.S. FDA Approves BELBUCA™ (buprenorphine) Buccal Film for Chronic Pain ManagementOctober 26, 2015 6:00 AM